CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines

Last updated: September 26, 2019
Project Number: RC1190-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What are the evidence-based guidelines regarding switching to a second-line therapy in patients with relapsing-remitting multiple sclerosis?

Key Message

One evidence-based guideline was identified with one strong recommendation regarding switching from an interferon or glatiramer acetate to a second-line therapy in patients with relapsing-remitting multiple sclerosis and evidence of disease activity. Consensus statements provided by the guideline suggest that there is insufficient evidence on patient factors or disease activity considerations to make more specific recommendations for switching to second-line treatments. The consensus statements presented in this report should be interpreted with caution based on the limitations and paucity of evidence.